Superworth

Spyre Therapeutics free cash flow SYRE

Cash from operations less capital spending, by quarter and over the last twelve months, from 2015.

Last 12 months, to Dec 31, 2023
n/m
a quarter missing
Latest quarter, Q4 FY23
−$31M
Fiscal year 2023
n/a

Spyre Therapeutics' twelve-month free cash flow can't be added up yet: a quarter of its results is missing from our data.

In its latest quarter, Q4 FY23, it was −$31M.

Free cash flow over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearFree cash flowChange
FY2023n/an/a
FY2022−$80.2Mn/a
FY2021−$54.3Mn/a
FY2020−$80.1Mn/a
FY2019−$67.2Mn/a
FY2018−$32.6Mn/a
FY2017−$25.2Mn/a
FY2016−$19.1Mn/a
FY2015−$11.2Mn/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedFree cash flowOn a year earlierLast 12 months
Q4 FY23−$31Mn/an/a
Q4 FY22−$18.1Mn/a−$80.2M
Q3 FY22−$15.1Mn/a−$81.3M
Q2 FY22−$20.7M−1107%−$83.3M
Q1 FY22−$26.3Mn/a−$60.6M
Q4 FY21−$19.3Mn/a−$54.3M
Q3 FY21−$17.1Mn/a−$53.2M
Q2 FY21$2.1Mn/a−$54.2M
Q1 FY21−$20Mn/a−$77M
Q4 FY20−$18.1Mn/a−$80.1M
Q3 FY20−$18.1Mn/a−$79.4M
Q2 FY20−$20.7Mn/a−$78.6M

Against its peers

Companies in Drug Manufacturers - General nearest Spyre Therapeutics' size, closest first, today.

CompanyFree cash flow yield
SYRESpyre Therapeuticsn/m
TGTXTG Therapeutics0.2%
ALKSAlkermes plc.3.0%
PTGXProtagonist Therapeutics1.5%
CORTCorcept Therapeutics1.2%
AMRXAmneal Pharmaceuticals2.0%
LGNDLigand Pharmaceuticals2.2%
KNSAKiniksa Pharmaceuticals International3.1%
BMRNBiomarin Pharmaceutical6.8%
JAZZJazz Pharmaceuticals11.5%
INDVIndivior Pharmaceuticals−2.7%
Peer median2.1%

What the free cash flow tells you

Cash from operations minus capital spending. The cash the company could hand back or reinvest.

Seasonal and lumpy quarter to quarter. The TTM view is the one to trust.

More on Spyre Therapeutics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.